Evidence map›Paper›PMID 36073830›Full record

ArticleThe Australasian journal of dermatology2022

Combination treatment of bilateral periocular sebaceous carcinomas with microsatellite instability with neoadjuvant pembrolizumab and Mohs surgery.

Alexander D Woods, Solomiya Grushchak, Kenya M Williams, Alan Tan, Aleksandar L Krunic

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Australasian journal of dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Alexander D WoodsDepartment of Dermatology, University of Illinois Chicago College of Medicine, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-8788-3525
Solomiya GrushchakDepartment of Dermatology, Cook County Health, Chicago, Illinois, USA.
Kenya M WilliamsDepartment of Ophthalmology, Rush University Medical Center, Chicago, Illinois, USA.
Alan TanDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Aleksandar L KrunicDepartment of Dermatology, Cook County Health, Chicago, Illinois, USA.
Cook County Health and Hospitals System · USRush University Medical Center · USIllinois College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case highlights the successful use of pembrolizumab for neoadjuvant treatment of MMR-deficient sebaceous carcinoma of bilateral eyelids to reduce tumour burden allowing smaller defect post-Mohs surgery and better reconstructive outcome. Microsatellite stability, tumour mutational burden and PD-L1 expression are important prognostic factors to be considered for the use of neoadjuvant pembrolizumab. Further studies are needed to determine if neoadjuvant pembrolizumab consistently improves surgical and cosmetic outcomes and reduces local recurrence and metastasis.

Indexed as

CarcinomaSebaceous Gland NeoplasmsAntibodies, Monoclonal, HumanizedHumansMicrosatellite InstabilityMohs SurgeryNeoadjuvant TherapyAntibodies, Monoclonal, Humanizedpembrolizumabcheckpoint inhibitorsimmunotherapyMohs surgeryMuir-Torre syndromeneoadjuvant therapyPD-1 inhibitorspembrolizumabsebaceous carcinomasebaceous gland neoplasms

Identifiers

PMID36073830
PMCPMC9825858
OpenAlexW4294992111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.